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David M. Kaye, MD, PHD*†
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Objectives This study sought to determine the potential pathophysiological link between anemia and disease severity, and
adverse outcome in heart failure (HF).
Background Anemia frequently accompanies advanced HF; however, the pathophysiological mechanism responsible for the
association between anemia and more severe HF remains uncertain. We hypothesized that a depletion of myo-
cardial iron content may provide the biological link.
Methods Complementary clinical and basic studies were performed. Hemodynamic, biochemical, and echocardiographic
investigations were performed in 9 healthy controls and 25 patients with advanced HF (left ventricular ejection
fraction: 23  10%). Tissue iron content and type 1 transferrin receptor (Tfr1) expression were assessed in hu-
man myocardial tissue, and the regulation of Tfr1 expression was studied in isolated cardiomyocytes.
Results HF patients displayed evidence of iron deficiency as measured by lower serum iron (p  0.05) and transferrin
saturation (TFS) (p  0.05). When subclassified according to the presence of anemia, TFS was lower in anemic
compared with nonanemic HF patients, whereas TFS in nonanemic HF patients was intermediate. In association,
myocardial iron content was reduced in HF versus non-HF samples (0.49  0.07 g/g vs. 0.58  0.09 g/g,
p  0.05), and there was a significant reduction (p  0.05) in the myocardial mRNA expression of Tfr1, which
plays a key role in cellular iron transport. In the context of HF, catecholamines and aldosterone both down-
regulated Tfr1 expression in isolated cardiomyocytes.
Conclusions This study suggests the presence of iron depletion in the failing human heart, providing a potential link for the
association between anemia and adverse prognosis in HF. (J Am Coll Cardiol 2011;58:474–80) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.059Anemia is a common comorbid factor in patients with heart
failure (HF) (1) and is characteristically associated with
greater functional impairment and worse New York Heart
Association functional class (2). Recently, particular interest
has been directed toward the strong inverse relationship
between the extent of anemia and survival (3–8). This
observation has subsequently been the logical basis of many
trials aimed at evaluating the hypotheses that reversal of
anemia may translate into improved survival for HF pa-
tients. Among these studies, several have evaluated the
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2011, accepted January 17, 2011.effect of the administration of erythropoietin and other
erythropoiesis-stimulating agents, with limited effect (9).
Despite the focus on anemia as a target for therapy in HF,
the cause of anemia in HF patients is a matter of ongoing
debate. Similarly, the mechanism by which the presence of
anemia contributes to an adverse outcome in these patients is
also unknown. Specifically, it is not known whether it is the
anemia per se that contributes to adverse prognosis or whether
it is one of the contributing factors to the anemia that also
contributes to adverse HF outcome or, alternatively, whether
anemia is simply a biomarker for advanced HF.
See page 481
In regard to the etiology of the anemia in HF, there is
growing evidence that iron availability may be reduced (1),
and recently, it has been suggested that iron deficiency itself
may be an independent predictor of outcome in HF (8).
Conceptually, this may result from either an absolute
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and/or occult bleeding (10). Alternatively, iron deficiency
may be relative, the result of dysregulation of iron homeo-
stasis and accumulation of iron in cells of the reticuloendo-
thelial system (11), which is a characteristic feature of
anemia of chronic disease (12). In support of the important
role of iron deficiency in HF patients, a recent trial of iron
supplementation demonstrated an improvement in func-
tional capacity and quality of life parameters (13).
In the present study, we aimed to test the hypothesis that
the association between anemia and HF severity, and
outcome might rather be explained by an underlying deple-
tion of iron stores, particularly at the myocardial level. This
concept is predicated on previous experimental work show-
ing that iron deficiency is associated with progressive left
ventricular dysfunction and cardiac fibrosis (14), although it
is not known whether a similar entity exists in humans. In
the context of HF, systemic and myocardial iron deficiency
could thus contribute both to anemia and HF progression.
In order to address this question, we performed a series of
complementary studies in controls and HF patients, includ-
ing biochemical and hemodynamic assessments and trans-
cardiac blood sampling. These studies were complemented
by determining tissue iron content and transferrin receptor
expression in human heart samples, and by investigating the
regulation of the transferrin receptor in cardiomyocyte cell
culture.
Methods
Patients and protocol. The clinical protocol was approved
by the Alfred Hospital Ethics Review Committee. We
studied 25 unselected consecutive patients (18 males and 7
females) with advanced HF and significantly impaired left
ventricular ejection fraction (LVEF) (35%), referred by
their managing physicians for hemodynamic assessment as a
component of a standardized inpatient evaluation for heart
transplantation. The cause of HF was ischemic heart disease
in 9 patients and nonischemic cardiomyopathy in 16 indi-
viduals. Medications included angiotensin-converting en-
zyme inhibitors/angiotensin receptor blockers (80%; median
dose 50% [interquartile range (IQR): 25% to 50%] of target
dose), beta-blockers (84%; median 50% [IQR: 25% to 50%]
of target dose), loop diuretics (100%; median 240 mg [IQR:
40 to 268 mg] furosemide), and spironolacatone (80%;
median 25 mg [25 to 50 mg]), and 84% had an implantable
defibrillator. Patients were included irrespective of their
hemoglobin (Hb) concentrations, and those on intravenous
inotropes, severe renal impairment (estimated glomerular
filtration rate [eGFR]: 30 ml/min/1.73 m2), acute or
hronic infection, known neoplasms, diseases of the gastro-
ntestinal tract, overt thyroid disease, and patients currently
reated with iron or erythropoiesis-stimulating agents or
reated with iron or erythropoiesis-stimulating agents dur-
ng the 3 months preceding the study were excluded. In
onjunction, we also studied a group of healthy volunteerubjects (n  9, 6 males and 3
emales) recruited from the gen-
ral community by advertisement.
ardiac catheterization. Car-
iac catheterization was per-
ormed in the nonfasting state
nd under full medication as ap-
ropriate. A 3-F arterial line was
laced in a radial or brachial artery
or blood pressure measurement
nd blood sampling. A coronary
inus catheter was inserted via an
ntroducer sheath placed in the
ight internal jugular or brachial
ein and positioned under fluoro-
copic control. Right heart pres-
ures and cardiac output were
ubsequently measured by Swan-
anz catheterization.
aboratory analysis. Hemoglobin, vitamin B12, folate, cre-
atinine, urea, high-sensitivity C-reactive protein (hs-CRP),
and N-terminal-pro-B-type natriuretic peptide were mea-
sured in peripheral venous blood using standard commercial
assays. Anemia was defined as Hb 13.0 g/dl in men or
12.0 g/dl in women (1). Iron, transferrin, soluble trans-
ferrin receptor, and ferritin levels were measured in arterial,
coronary sinus, and peripheral venous blood using standard
clinical assays. Transferrin saturation (TFS) was calculated
from iron and transferrin (15). Transcardiac gradients and
whole-body arteriovenous differences in various biochemical
indexes were calculated and are presented in the subsequent
text. All analyses were performed in the clinical laboratory
of the Alfred Hospital.
Human myocardial tissue iron content and transferrin
receptor expression. Myocardial tissue samples were ob-
tained from the explanted failing hearts of a separate cohort
of patients at the time of transplantation (n  6, 5 males,
age 46  12 years) and from unused donor hearts (n  5,
5 males, age 38  18 years, p  NS vs. HF samples).
Myocardial iron content was determined by atomic adsorp-
tion spectroscopy (Regional Laboratory Services, Benalla,
Australia). Total RNA was extracted using Trizol (Invitro-
gen, Carlsbad, California). Following reverse transcription,
real-time polymerase chain reaction (PCR) was performed
using a PCR 7300 (Applied Biosystems, Foster City,
California) thermocycler to investigate the expression of
the type 1 transferrin receptor (Tfr1) using the primer pairs:
(rat) forward: 5=-GAATAC GTTCCCCGTTGTTGA-3=,
reverse: 5=-ATCCCCAGTTCCTAGATGAGCAT-3= or
(human) forward: 5=-GTGACCCTTACACAGCTGG-
ATTC-3=, reverse: 5=-TGATGACCGAGATGGTGG-3=
together with the housekeeping genes 18S and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as appropriate. Quan-
titative data are expressed in Ct format.
Transferrin receptor expression in cardiomyocytes. Neo-
Abbreviations
and Acronyms
eGFR  estimated
glomerular filtration rate
Hb  hemoglobin
HF  heart failure
hs-CRP  high-sensitivity
C-reactive protein
IQR  interquartile range
LVEF  left ventricular
ejection fraction
PCR  polymerase chain
reaction
Tfr1  type 1 transferrin
receptor
TFS  transferrin
saturationnatal rat cardiomyocytes and cardiac fibroblasts were iso-
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exposure to neurohormones of relevance to HF on transfer-
rin receptor expression was examined by real-time PCR as
described in the previous text in n 4 separate experiments.
Statistical analysis. Categorical data are given as counts
and percentages, and continuous data are presented as mean
SD or median (interquartile range), as appropriate.
Between-group comparisons were performed using chi-
square tests, unpaired t tests, or Mann-Whitney U tests, as
appropriate. Comparisons between multiple groups were
performed using 1-way analysis of variance or Kruskal-
Wallis tests followed by Tukey tests or Mann-Whitney test,
respectively, the latter with the p value adjusted for multiple
testing (Bonferroni correction). Correlations between pa-
rameters of interest were assessed using Pearson correlation
coefficients after ln-transformation of data with skewed
distribution. Analysis was performed using commercially
available software packages (SPSS, version 15.0, SPSS, Inc.,
Chicago, Illinois, and SigmaPlot, version 10.0, Systat Soft-
ware Inc., San Jose, California).
Results
Clinical, laboratory, and hemodynamic features. As ex-
pected, controls and HF patients differed significantly with
regard to LVEF (66  9% vs. 23  10%, p  0.01),
N-terminal-pro-B-type natriuretic peptide (53 ng/l [IQR:
23 to 90 ng/l] vs. 2,654 ng/l [IQR: 1,313 to 5,926 ng/l],
p  0.01), eGFR (90  24 ml/min/1.73 m2 vs. 70  20
ml/min/1.73 m2, p  0.05), Hb (140  9 g/l vs. 124  20
/l, p  0.05), but did not differ in regard to body mass
ndex. In regard to hematinic status, controls and HF
atients differed significantly with regard to serum iron
18.4 4.8 mol/l vs. 12.3 7.0 mol/l, p 0.05), serum
transferrin (2.47 g/l [IQR: 2.20 to 2.60 g/l] vs. 2.84 g/l
Clinical and Biochemical Characteristics AccordTable 1 Clinical and Biochemical Character
Controls
(n  9)
Age, yrs 56 15
Hemoglobin, g/l 140 9
LVEF, % 66 9
NT-proBNP, ng/l 53 (22–90
Mean arterial pressure, mm Hg 95 15
Cardiac output, l/min 6.4 1.
PCWP, mm Hg 8 3
eGFR, ml/min/1.73 m2 92 24
Iron, mol/l 18.4 4.
Transferrin, g/l 2.47 (2.20–2
Transferrin saturation, % 30.3 10
Soluble transferrin receptor, mg/l 2.9 (2.5–3.
High-sensitivity C-reactive protein, mg/l 1.1 (0.8–3.
Values are mean SD or median (interquartile range). *p 0.05 versu
control.eGFR  estimated glomerular filtration rate; HF  heart failure; LVEF 
natriuretic peptide; PCWP  pulmonary capillary wedge pressure.[IQR: 2.58 to 3.13 g/l], p  0.05), and TFS (30.3  10.2%
vs. 17.3  9.5%, p  0.05), whereas serum ferritin did not
differ (100  57 g/l vs. 124  90 g/l, p  NS).
In order to investigate the potential basis for the adverse
association of anemia with HF severity, patients were
stratified into the presence or absence of anemia defined by
the criteria in the previous text. As shown in Table 1, HF
patients with or without anemia did not differ significantly
with regard to their hemodynamic profile at rest or with
respect to renal function. Anemic HF patients displayed
evidence of iron deficiency as reflected by lower serum iron
and lower TFS as compared with both healthy controls and
nonanemic HF patients. In conjunction, TFS was also
lower in the nonanemic HF patients as compared with
healthy controls (Fig. 1). Anemic HF patients as compared
with nonanemic HF patients did not significantly differ with
regard to their use and doses of angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers (78% vs.
82%, p 0.84; 25% [IQR: 25% to 27%] vs. 50% [IQR: 25%
to 67%] of target dose, p  0.06), beta-blockers (67% vs.
94%, p  0.08; 50% [IQR: 48% to 108%] vs. 50% [IQR:
25% to 50%] of target dose, p 0.14), loop diuretics (100%
in both groups, 160 mg [IQR: 80 to 310 mg] vs. 240 mg
[IQR: 73 to 290 mg] furosemide, p  0.71), and spironolo-
actone (78% vs. 88%, p  0.92; 25 mg [IQR: 25 to 25 mg]
vs. 25 mg [IQR: 25 to 50 mg], p  0.44), or device therapy
(data not shown).
There was a very strong (r2  0.70, p  0.001) associa-
ion between TFS and Hb across the entire cohort (Fig. 1),
hereas there was no significant association between Hb
nd ferritin (r  0.18; p  0.38), folate (r  0.19; p 
.37), vitamin B12 (r  0.24; p  0.25), eGFR (r  0.12;
p  0.58), or ln hs-CRP (r  0.28; p  0.15).
Whole-body and cardiac iron status in HF. In order to
develop a biochemical assessment of whole-body iron turn-
o AnemiaAccording to Anemia
HF  Anemia
(n  16)
HF  Anemia
(n  9)
51 16 52 9
136 4 103 15†‡
22 8* 26 6‡
2,551 (1,599–6,287)* 3,685 (1,174–6,764)‡
79 12* 71 6‡
3.4 0.8* 3.6 0.9‡
24 4* 21 6‡
70 24 69 21
15.2 6.8 7.1 3.6‡†
2.79 (2.56–3.07)* 2.98 (2.62–3.19)‡
21.3 8.8* 10.0 6.6‡†
4.4 (3.0–4.8)* 10 (4.5–13.9)‡†
5.8 (2.4–8.5)* 5.3 (1.8–9.4)
hy control; †p 0.05 versus nonanemic HF; ‡p 0.05 versus healthying tistics
)
5
8
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difference in the TFS, given the greater sensitivity of the latter
measure as an index of iron status. As shown in Figure 2, there
was evidence of a net arteriovenous gradient in TFS in healthy
controls, whereas little evidence existed in either of the HF
cohorts, the differences being statistically significant.
In an attempt to directly investigate the uptake of iron by
the myocardium, we determined the transcardiac concen-
tration gradients for each relevant parameter. This analysis,
however, showed only very small differences in concentra-
tions for iron, transferrin, and TFS, likely due in part to the
sensitivity of the respective assays together with the rela-
Figure 1 TFS in Healthy Subjects and HF Patients
(A) Bar graph showing transferrin saturation (TFS) in control patients and non-
anemic and anemic heart failure (HF) patients. *p  0.05 versus controls;
#p  0.05 versus nonanemic HF. Data are expressed as mean  SEM.
(B) Scatterplot with regression line demonstrating the relationship between
ln-transformed transferrin saturation and hemoglobin.tively small organ mass compared with body weight.To extend our observations, we next determined the
tissue content of iron in samples of nonfailing unused donor
and failing human left ventricular myocardial samples, as
determined by atomic adsorption spectroscopy. As shown in
Figure 3, the tissue content of iron was significantly lower in
the failing heart. Given the role of the transferrin receptor as
the major uptake pathway for the transport of iron into the
myocardium, we also examined the expression of Tfr1 in the
nonfailing and failing human heart. As shown in Figure 3,
we observed a 68% reduction (p  0.05) in the level of Tfr1
mRNA expression.
Regulation of myocardial transferrin receptor expression.
To investigate the potential basis for the observed down-
regulation of Tfr1 in the failing heart, we investigated the
regulation of the receptor in isolated rat ventricular cardio-
myocytes, using cell culture conditions of relevance to the
HF paradigm. As shown in Figure 4, exposure to the
neurohormones norepinephrine (107 mol/l) and aldoste-
one (107 mol/l) both resulted in a significant down-
egulation of mRNA for Tfr1. To establish the basis for the
orepinephrine-induced decrease in Tfr1 expression, we
ompared the effects of 48-h exposure to the alpha- and
eta-adrenoceptor agonists phenylephrine (106 mol/l) and
soprenaline (106 mol/l), respectively. As shown in Figure 4,
the beta-agonist caused a 25% (p  0.05) reduction in
receptor expression, whereas the alpha-agonist exerted no
apparent effect. The influence of B-type natriuretic peptide
(107 mol/l) was also examined and found to be without
ffect on Tfr1 mRNA expression. In conjunction, we tested
he effect of the neurohormones on Tfr1 mRNA levels in rat
ardiac fibroblasts, and these were found not to alter gene
xpression.
iscussion
n the present study, we investigated the potential basis for
he strong association between anemia and adverse progno-
Figure 2 AV Differences in TFS
Bar graph depicting the arteriovenous (AV) difference in TFS in healthy subjects
and nonanemic and anemic HF patients. *p  0.05 versus controls. Data are
expressed as mean  SEM. Abbreviations as in Figure 1.
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per se may be the responsible mechanism rather than the
effects of a low Hb itself. In our study, we observed that
patients with advanced HF exhibited a lower Hb that was
accompanied by biochemical indices of iron deficiency.
When classified according to the presence or absence of
anemia, HF patients displayed an even greater degree of
iron deficiency, although nonanemic HF patients also had
evidence of intermediate iron deficiency as measured by
their TFS.
Previous studies of the prevalence of anemia in patients
with HF report ranges between 15% and 70%, according to
the setting of the study (1). Consistent with these studies, in
the current study, 36% of our unselected, consecutive
patients with advanced HF were anemic. As indicated in the
previous text, the intense interest in the role of anemia in
HF has arisen because of its association with adverse
prognosis (3–7). It has also been reported from cross-
sectional studies that anemia is associated with older age,
renal impairment, and poorer hemodynamics (16), although
we did not observe this in the present study.
Although the epidemiology of anemia in HF has been
Figure 3 Myocardial Iron and Transferrin Receptor Expression
(A) Bar graphs comparing the iron content of failing and nonfailing human
heart samples. (B) Bar graphs comparing the transferrin receptor mRNA abun-
dance, expressed as  Ct values (vs. control). Fold difference  2 Ct.
Data are expressed as mean  SEM. Trfr1  type 1 transferrin receptor.well characterized, the underlying mechanism remainspoorly understood. Currently, 3 major mechanisms have
been proposed for the anemia of HF, including impaired
erythropoietin production or signaling, iron deficiency, or
an anemia of chronic disease, perhaps due to the actions of
inflammatory cytokines (1). Previous studies of erythropoi-
etin in HF have yielded conflicting results, including the
presence of high plasma levels (17). We did not measure the
levels of erythropoietin in our cohort. The possibility that a
relative deficiency of erythropoietin is the driving mecha-
nism for anemia in HF has led to a number of trials,
including ongoing large-scale trials. As recently reviewed
(1), although therapy with erythropoiesis-stimulating agents
resulted in a consistent rise in Hb in the larger studies
(9,18), the impact on clinical measures has varied, and
definitive outcome data are still awaited. These findings are
of relevance to the hypothesis that the relationship between
anemia and adverse outcome in HF is the result of the
requirement for an increase in cardiac output to provide
appropriate oxygen delivery. In our study, we did not find
Figure 4 Regulation of Transferrin Receptors
(A) Bar graphs comparing transferrin receptor (Tfr1) mRNA expression in control
and norepinephrine (NE) (107 mol/l) or aldosterone (Aldo) (107 mol/l) treated
cardiomyocytes. (B) Bar graphs comparing transferrin receptor mRNA expression
in control and isoprenaline (ISO) (106 mol/l) or phenylephrine (Phe) (106 mol/l)
treated cardiomyocytes (n  4). Data are expressed as  Ct values (vs. control).
Fold difference  2 Ct. Data are expressed as mean  SEM. *p  0.05.
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patients. This hypothesis is also potentially negated by the
ability of the hemoglobin–oxygen dissociation curve to be
modulated by other well-known intracellular means, includ-
ing the levels of 2,3-diphosphoglycerate.
As indicated in the previous text, we demonstrated strong
evidence for the presence of graded levels of iron deficiency
in our HF patients, being most profound in the anemic
group. As such, it is possible that anemia only becomes
apparent in HF when total-body iron stores are sufficiently
depleted, a concept that is supported by our demonstration
of a strong relationship between TFS and Hb. Our popu-
lation of patients with advanced HF was similar to the
population with HF and anemia studied by Nanas et al.
(10), who found that approximately three-quarters of these
patients had an iron-deprived bone marrow despite normal
ferritin. These authors concluded that anemia was due to
absolute iron deficiency in the majority of cases (10). In our
study, we also attempted to assess whole-body iron tissue
uptake based upon the arteriovenous change in TFS. To the
best of our knowledge, this parameter has not be measured
before in either healthy subjects or controls. Previous
investigators have used oral 59Fe radiotracers to study
gastrointestinal uptake; however, such studies (19) have
tended to show varied uptake even in normal volunteers and
with a limited relationship to hematinic parameters. In our
study, the arteriovenous TFS gradient was significantly
reduced in both nonanemic and anemic HF patients,
suggesting a generalized reduction in iron uptake. However,
others have argued that increased storage of iron in the
reticuloendothelial system and decreased systemic iron
availability could have resulted in iron depletion of the bone
marrow despite normal total-body iron (11). From our data,
it is not possible to tell whether patients had absolute iron
deficiency (reduced iron stores) or relative iron deficiency
(decreased systemic iron availability despite overall normal
total/body iron). Other investigators have proposed that a
chronic inflammatory state contributes to the anemia of HF;
however, in the present study, we did not observe any
differences in the levels of hs-CRP across any of the patient
groups.
Based on our demonstration that iron stores are reduced
in HF and that this likely reflects a generalized disorder, we
next evaluated the possibility that a reduction in the content
of iron in the myocardium may occur in HF. To the best of
our knowledge, we showed for the first time that the iron
content of the failing human heart is reduced compared
with nonfailing hearts. In conjunction, we attempted to
measure the transcardiac gradients for relevant parameters
of iron metabolism; however, no consistent gradients were
evident, likely due to the relatively small fractional uptake
together with the limited sensitivity of the associated assays.
Previously, it has been shown that animal models of iron
deficiency develop progressive cardiac fibrosis (14) as well as
other ultrastructural, macroscopic, and functional changes
of the left ventricular myocardium (20–23), highlightingthat cardiac iron uptake and intracellular iron handling may
be critical for cardiac function. As such, it is possible that
iron depletion in the failing human heart may contribute to
disease progression. This concept could be consistent with
the recent demonstration that iron supplementation in HF
patients appears to be associated with improvements in
clinical parameters (13) and, conversely, that iron deficiency
appears to be an independent predictor of survival (8).
Iron plays a key intracellular role in many cell types, and
in cardiac myocytes, this includes an important role within
mitochondria and in myoglobin. In the circulation, iron is
extensively carried by transferrin, the latter performing a
role both as a transport protein and as a mechanism to
maintain iron in a nonreactive state (24). In order for iron to
be taken up by cells, transferrin binds to specific receptors,
including Tfr1, which interacts with other intracellular
proteins including beta2 microglobulin and an MHC class
I-type protein encoded by the hemochromatosis-associated
gene, HFE. In the present study, we observed reduced Tfr1
mRNA expression in the failing heart, providing in part a
further explanation for the reduced levels of iron in the failing
heart. This notion is further supported by previous stud-
ies demonstrating a close association between Tfr1 mRNA
gene expression, Tfr1 protein abundance, and iron transport
(25–27). To investigate the potential mechanism for this
finding in the context of HF, we found that neurohormones
that are increased in HF, aldosterone and norepinephrine,
reduced the expression of Tfr1 in cardiomyocytes. Further-
more, the decrease in Tfr1 gene expression mediated by
norepinephrine appeared to be predominantly mediated via the
beta-receptor. In addition to the putative role of neurohor-
mones as regulators of Tfr1, previous studies in nonmyocardial
cells have shown that cytokines such as interferon-gamma can
down-regulate Tfr1, whereas hypoxia inducible factor-1 can
up-regulate Tfr1 (28).
Study limitations. Given the invasive nature of our study,
we included a relatively limited number of healthy volun-
teers and HF subjects. Accordingly, although our study
provided an opportunity to test our novel hypotheses, the
limited sample size restricts our capacity to explore more
detailed relationships between various factors that may
contribute to alterations in iron homeostasis in vivo. One of
our key objectives was to compare the uptake of iron in the
normal and failing myocardium by evaluating the transcardiac
concentration gradient for iron. No arteriovenous difference
could be detected, presumably due to the combined limitation
of assay sensitivity and the relatively small concentration
gradient. To complement these studies, we also measured the
myocardial iron concentration and Tfr1 gene expression, which
revealed significantly lower levels of both in the failing heart. In
this analysis, it is not possible to exclude an effect of replace-
ment fibrosis; however, we demonstrated that unlike in cardi-
omyocytes, the expression of Tfr1 does not appear to alter in
cardiac fibroblasts in the context of neurohormonal stimula-
tion. We also acknowledge that the study is limited by the fact
that we did not measure erythropoietin and reticulocyte counts,
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the study population.
Conclusions
We provide evidence for both systemic and myocardial
deficiency of iron in patients with advanced HF. Anemic
patients displayed features of more pronounced iron defi-
ciency, which may translate into a greater degree of iron
depletion. Thus, further studies that incorporate the routine
measurement of cardiac iron stores and the longitudinal
effects of iron replenishment are warranted in HF patients.
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